Volume 64, Issue 3, Pages (September 2003)

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Steven Fishbane, Jeffrey S. Berns, M.D. Kidney International

Volume 59, Issue 3, Pages (March 2001)

Volume 65, Issue 6, Pages (June 2004)

Volume 62, Issue 3, Pages (September 2002)

Volume 59, Issue 3, Pages (March 2001)

Beta blockers in the management of chronic kidney disease

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease Kevin E. Chan, Ravi I. Thadhani,

End-stage renal disease in developing countries

Volume 83, Issue 3, Pages (March 2013)

Volume 63, Issue 6, Pages (June 2003)

Volume 70, Issue 6, Pages (September 2006)

C-reactive protein and dialysis access

Volume 55, Issue 2, Pages (February 1999)

Kidney transplantation in a low-resource setting: Nigeria experience

Volume 62, Issue 3, Pages (September 2002)

Volume 61, Issue 4, Pages (April 2002)

Volume 80, Issue 10, Pages (November 2011)

C-reactive protein and dialysis access

Burden of chronic kidney disease: North Africa

Volume 54, Issue 2, Pages (August 1998)

Francesco Paolo Schena Kidney International

Volume 85, Issue 3, Pages (March 2014)

Volume 63, Issue 2, Pages (February 2003)

Abnormalities in lipoprotein metabolism in hemodialysis patients

Comorbidity and confounding in end-stage renal disease

Volume 70, Issue 11, Pages (December 2006)

Joseph W. Eschbach, John W. Adamson Kidney International

Volume 57, Issue 6, Pages (June 2000)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

This Month in AJKD American Journal of Kidney Diseases

Nephrology Crosswords: Hemodialysis

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Blood pressure targets in hemodialysis patients

Fructose intake as a risk factor for kidney stone disease

Response to ‘Hepcidin levels in patients with renal disease’

Volume 65, Issue 6, Pages (June 2004)

Volume 76, Issue 6, Pages (September 2009)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Elevated risk of stroke among patients with end-stage renal disease

Alternate-day dialysis may be needed for hemodialysis patients

Counteracting progression of renal disease: A look into the future

Lynda Anne Szczech, Ira L. Lazar Kidney International

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

Volume 65, Issue 3, Pages (March 2004)

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Volume 62, Issue 3, Pages (September 2002)

Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass

Wei-Teing Chen, Horng-Chin Yan, Fu-Chiu Yu Kidney International

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Current status of maintenance hemodialysis in Beijing, China

The Iranian model of living renal transplantation

The Danish Renal Biopsy Register

Volume 80, Issue 10, Pages (November 2011)

Elevated plasma F2-isoprostanes in patients on long-term hemodialysis

Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction Malcolm F. Hand, William G. Haynes, David J.

Volume 80, Issue 10, Pages (November 2011)

Is complement a target for therapy in renal disease?

Volume 70, Issue 5, Pages (September 2006)

Changes to the End-Stage Renal Disease Quality Incentive Program

Volume 59, Issue 3, Pages (March 2001)

Volume 59, Issue 3, Pages (March 2001)

Volume 70, Issue 10, Pages (November 2006)

Hemodialysis access failure: a call to action—revisited

Stephen Pastan, J. Michael Soucie, William M. McClellan

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 64, Issue 3, Pages 978-991 (September 2003) Alpha and gamma tocopherol metabolism in healthy subjects and patients with end- stage renal disease Jonathan Himmelfarb, Jane Kane, Ellen Mcmonagle, Eric Zaltas, Steve Bobzin, Sekhar Boddupalli, Stephen Phinney, Guy Miller Kidney International Volume 64, Issue 3, Pages 978-991 (September 2003) DOI: 10.1046/j.1523-1755.2003.00151.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Structures of alpha, beta, gamma, and delta tocopherols and alpha, beta, gamma, and delta carboxyethyl-hydroxychromans (CEHCs). Kidney International 2003 64, 978-991DOI: (10.1046/j.1523-1755.2003.00151.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Serum alpha and gamma tocopherol (A) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B) levels in healthy controls and hemodialysis patients after a 600mg dose of alpha tocopherol at day 0. Kidney International 2003 64, 978-991DOI: (10.1046/j.1523-1755.2003.00151.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Serum alpha and gamma tocopherol (A) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B) levels in healthy controls and hemodialysis patients after a 600mg dose of gamma-enriched tocopherols at day 0. Kidney International 2003 64, 978-991DOI: (10.1046/j.1523-1755.2003.00151.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Serum alpha and gamma tocopherol (A) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B) levels in healthy controls and hemodialysis patients during a 14-day course of 300mg alpha tocopherol/day. Kidney International 2003 64, 978-991DOI: (10.1046/j.1523-1755.2003.00151.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Serum alpha and gamma tocopherol (A) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B) levels in healthy controls and hemodialysis patients during a 14-day course of 300mg gamma-enriched tocopherols/day. Kidney International 2003 64, 978-991DOI: (10.1046/j.1523-1755.2003.00151.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 6 C-reactive protein (CRP) after 14days of (A) alpha-enriched tocopherol or (B) gamma-enriched tocopherol. Symbols are: (▪) individual patients; (□) mean of all patients. Kidney International 2003 64, 978-991DOI: (10.1046/j.1523-1755.2003.00151.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 7 Interleukin-6 (IL-6) in hemodialysis patients at day 0 and day 14 of (A) alpha-enriched tocopherol or (B) gamma-enriched tocopherol. Symbols are: (▪) individual patients; (□) mean of all patients. Day 0 vs. day 14, P = 0.04. Kidney International 2003 64, 978-991DOI: (10.1046/j.1523-1755.2003.00151.x) Copyright © 2003 International Society of Nephrology Terms and Conditions